Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    cocomo
Previous Study | Return to List | Next Study

Copenhagen Co-morbidity in HIV Infection Study (COCOMO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02382822
Recruitment Status : Active, not recruiting
First Posted : March 9, 2015
Last Update Posted : February 12, 2019
Sponsor:
Information provided by (Responsible Party):
Susanne Dam Nielsen, MD, Rigshospitalet, Denmark

Brief Summary:
Despite efficient antiretroviral treatment for HIV infection, decrease in life expectancy remains. Excess mortality is mainly due to non-AIDS co-morbidity including cardiovascular, pulmonary, and liver related diseases. Both HIV-unrelated and HIV-related risk factors probably contribute to this pattern. At present, most evidence regarding co-morbidity in HIV infection rely on cross-study comparisons of HIV-infected persons with published population rates and few prospective studies in U.S. cohorts. Using well characterized participants from the Copenhagen General Population Study (CGPS) as controls, we aim to include >1500 HIV-infected persons in the COCOMO study to determine if co-morbidity is more prevalent or develops at a higher rate in HIV-infected persons. The study will asses 1) cardiovascular, 2) pulmonary and 3) liver-related co-morbidity using uniformly collected data in the two cohorts. The investigators aim to study the relative impact of HIV-unrelated and HIV-related factors on development of co-morbidity.

Condition or disease Intervention/treatment
HIV COPD CVD Liver Disease Other: No intervention.

Detailed Description:

Primary hypothesis:

Cardiovascular disease:

- HIV infection is independently associated with higher prevalence of coronary atherosclerosis (assessed by CT angiography)

Obstructive pulmonary disease:

- HIV infection is independently associated with higher prevalence of COPD, and independently associated with loss of lung function

Liver disease:

- HIV infection is independently associated with liver steatosis, steatohepatitis and liver fibrosis

Lipid and fat metabolism:

- HIV infection is independently associated with alterations in adipose fat tissue and dyslipidemia

Secondary hypothesis:

Cardiovascular disease:

  • Viral load and CD4 are independently associated with coronary atherosclerosis (assessed by CT angiography) in HIV-infected individuals.
  • Levels of inflammatory markers can predict coronary atherosclerosis in HIV-infected individuals.
  • Microbial translocation and metabolism are associated with coronary atherosclerosis in HIV-infected individuals.
  • Endothelial dysfunction (assessed by arterial elastography) can predict coronary atherosclerosis in HIV-infected individuals

Obstructive pulmonary disease:

  • Viral load and CD4 is independently associated with emphysema
  • HIV is independently associated with pulmonary hypertension (assessed by CT angiography), and obstructive lung disease is independently associated with airway obstruction
  • PCP colonization in HIV infected patients is independently associated with obstructive lung disease, emphysema and loss of lung function.
  • Inflammatory markers in HIV infected patients are associated with obstructive lung disease and loss of lung function

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1500 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Copenhagen Co-morbidity in HIV Infection Study
Study Start Date : March 2015
Estimated Primary Completion Date : March 2025
Estimated Study Completion Date : March 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Group/Cohort Intervention/treatment
HIV infected
Exposure to: Computed tomography(CT) of chest and upper abdomen, CT angiography(CTa) of heart, spirometry, mouth wash, eNO assessment, ankle brachial pressure index, fibroscan, blood sampling
Other: No intervention.
HIV uninfected
Exposure to: Computed tomography(CT) of chest and upper abdomen, CT angiography(CTa) of heart, spirometry, eNO assessment, ankle brachial pressure index, blood sampling
Other: No intervention.



Primary Outcome Measures :
  1. Coronary atherosclerosis [ Time Frame: Baseline cross-sectional data and after 2 years follow-up ]
    Prevalence of coronary atherosclerosis; electrocardiographic abnormalities and peripheral artery disease

  2. Obstructive pulmonary disease [ Time Frame: Baseline cross-sectional data and after 2 years follow-up ]
    Emphysema, airflow limitation,

  3. Liver disease [ Time Frame: Baseline cross-sectional data and after 2 years follow-up ]
    Prevalence of hepatic steatosis, steatohepatitis and liver fibrosis

  4. Lipid and fat metabolism [ Time Frame: Baseline cross-sectional data and after 2 years follow-up ]
    Visceral adipose tissue, dyslipidemia, gut microbiota

  5. Inflammation and clonal hematopoiesis [ Time Frame: Baseline cross-sectional data and after 2 years follow-up ]
    Cytokines (e.g. IL-6, TNF-alfa), cell subsets (e.g. Tregs, Th17)


Secondary Outcome Measures :
  1. Emphysema, P. jirovecii colonization [ Time Frame: Baseline data(cross-sectional data) ]
    Secondary pulmonary outcome measures

  2. Depression [ Time Frame: Baseline data (cross-sectional data) ]
    Major Depression Inventory Score, kynurenin/tryptophan ratio

  3. Bone metabolism [ Time Frame: Baseline data(cross-sectional data) assessed after two years ]
    Bone mineral density

  4. Hematological abnormalities [ Time Frame: Baseline data(cross-sectional data) ]
    Anemia, trombocytopenia, leukopenia

  5. Renal function [ Time Frame: Baseline data(cross-sectional data) ]
    Kidney function


Biospecimen Retention:   Samples With DNA
Routine biochemistry, whole blood, plasma, peripheral blood mononuclear cells (PBMCs), DNA and RNA from buffy coat, plasma, and red blood cells (RBC).


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
HIV infected patients.
Criteria

Inclusion Criteria:

  • signed informed consent
  • patients that are unable to understand information material
  • HIV infected

Exclusion Criteria:

Computed tomography(CT):

  • contraindications to CT and contrast (i.e. pregnancy, renal impairment, allergy to contrast media, allergy or contraindication to beta blocking agent, body weight more than 120kg, evidence of ongoing myocardial ischemia, heart rhythm precluding EKG gating)

Spirometry:

  • relative contraindications to spirometry (i.e. chest, abdominal or eye surgery within the 3 months before baseline spirometry, and known retinal detachment)
  • allergy or contraindications to salbutamol (i.e. >110 bpm, or a known uncontrolled cardiac condition (i.e. unstable coronary artery disease, decompensated heart failure)
  • a respiratory illness with at least two symptoms of breathlessness, cough, wheezing, or increase in sputum production within 6 weeks.

MRI:

  • Implants (e.g. pacemaker, coclea implants, insulin pumps)
  • Claustrophobia
  • Pregnancy

Liver Biopsy:

  • Risk of bleeding
  • Infection in puncture site

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02382822


Locations
Layout table for location information
Denmark
University Hospital of Copenhagen
Copenhagen, Denmark, 2100
Sponsors and Collaborators
Rigshospitalet, Denmark
Investigators
Layout table for investigator information
Study Director: Andreas Ronit, MD Department of Infectious Diseases
Study Director: Ditte M Kirkegaard-Klitbo, MD Department of Infectious Diseases
Study Director: Marco Gelpi, MD Department of Infectious Diseases
Study Director: Andreas D Knudsen, MD Department of Infectious Diseases
Study Director: Rebekka Faber, MD Department of Infectious Diseases

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Susanne Dam Nielsen, MD, MD, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier: NCT02382822     History of Changes
Other Study ID Numbers: Sponsor- Rigshospitalet
First Posted: March 9, 2015    Key Record Dates
Last Update Posted: February 12, 2019
Last Verified: February 2019

Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Acquired Immunodeficiency Syndrome
Liver Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Digestive System Diseases